product name Mitomycin C
Description: Mitomycin C is an antineoplastic antibiotic that inhibits DNA synthesis, and is used to treat different cancers. Mitomycine C is a methylazirinopyrroloindoledione analog isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.
References: Mol Cell. 2009 Sep 11;35(5):704-15; Cell Cycle. 2012 Sep 1;11(17):3312-23.
334.37
Formula
C15H18N4O5
CAS No.
50-07-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 67 mg/mL (200.4 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19411462
| In Vitro |
In vitro activity: Mitomycin C, by inducing DNA interstrand crosslinks, physically blocks DNA replication, recombination, and RNA transcription. Mitomycin C potentiates TRAIL-induced apoptosis in HCT116 (p53-/-) colon cancer cells and sensitizes TRAIL-resistant colon cancer cells HT-29 to the cytokine by through JNK-independent upregulation of death receptors. In different human cancer cell lines, such OVCAR-5 (ovary), HT-29 (colon), SK-N-MC (neuroblastoma), HEP-2 (liver), COLO-205 (colon), NIH-OVCAR-3 (ovary) and A-549 (lung) cells, Mitomycin C shows cytotoxic activity. Kinase Assay: Cell Assay: Mitomycin-C enhanced TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis in p53 deficient colon cancer HCT116 cells. In the cell viability assay, pretreated with 5M with mitomycin C for 24h and then exposure to 25ng/ml TRAIL and 5M mitomycin C for 12h in HCT116 cells showed surprisingly decreased cell viability. In the crystal violet staining assay showed 5M mitomycin C combinated 25ng/ml TRAIL can substantially enhanced suppression effects of HCT116 cells. Pretreatment with 5M mitomycin C can enhanced TRAIL initiated processing of caspase-8, -9, -3 and cleavage of RARP (poly-ADP-ribose polymerase, substrate of caspase-3). The western blot assay showed in both HCT116 and HT29 cells, mitomycin C suppressed the expression anti apoptotic proteins Mcl-1, Bcl-2, Bcl-XL, and downregulated caspase-inhibitor c-IAP-1, XIAP, while upregulated expression of pro-apoptotic proteins Bax and Bim. |
|---|---|
| In Vivo | The NMRI-Fox1nu nude mice was inoculated subcutaneously and then randomized to several groups: treated with electrochemotherapy and administrated 5mM mitomycin C or electrochemotherapy only or 5mM mitomycin C only. Results showed that tumor volume reduced in electrochemotherapy plus mitomycin C group, and mice survival rates were greater in electrochemotherapy plus mitomycin C group and mitomycin C group only, compared controls(p＜0.001). The tumor response rate was 53% for mitomycin C alone |
| Animal model | Rat bladder tumor model |
| Formulation & Dosage | Dissolved in saline; 400 μM; Intravesical injection |
| References | Mol Cell. 2009 Sep 11;35(5):704-15; Cell Cycle. 2012 Sep 1;11(17):3312-23; Int J Oncol. 2014 Jan;44(1):147-52. |
